Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations
June 07 2021 - 8:00AM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm’ with its lead drug
candidate, lenzilumab, today announced the appointment of Ken
Trbovich to the newly-created role of SVP of Investor Relations,
effective immediately, reporting to Timothy E. Morris, COO/CFO of
Humanigen.
Mr. Trbovich brings to Humanigen 20 years of experience on Wall
Street as a Managing Director and Senior Analyst at several leading
investment banks including Janney Montgomery Scott, MLV & Co.
(now part of B. Riley), C.E. Unterberg, Towbin (now part of
Canaccord Genuity), and Royal Bank of Canada. During the course of
his career he has analyzed developments at more than 100 companies
and produced over 2,000 research reports, and has developed an
extensive network of investors, analysts and investment bankers.
Ken also has experience working with multiple biopharmaceutical
companies at the start-up to commercial stage in a variety of
disease indications. He has an MBA from Thunderbird School of
International Management, earned a CFA designation, and has held
multiple FINRA licenses.
“Humanigen is pleased to welcome Ken,” said Cameron Durrant, CEO
of Humanigen. “His background and extensive skills on Wall Street
and in the biopharmaceutical space will be instrumental to
Humanigen as we progress our pipeline plans.”
“Ken’s work as a covering analyst for two decades and more
recently as an entrepreneur brings a unique and valuable skill
set,” commented Timothy E. Morris COO/CFO of Humanigen. “We are
fortunate to add Ken at this critical time in the company’s growth
and look forward to leveraging his network and experience with
current and future shareholders.”
Mr. Trbovich will be responsible for interfacing with investors
and analysts as a key member of the Humanigen management team as
the company prepares for potential distribution of lenzilumab for
COVID-19 under Emergency Use Authorization, and as Humanigen
expands its pipeline programs.
“I am excited to join Humanigen and utilize my market expertise
to help the company continue to advance in the biopharmaceutical
field,” says Ken Trbovich. “With Humanigen’s recent submission for
Emergency Use Authorization for lenzilumab, the team is working to
take Humanigen to the next level for commercialization and I am
looking forward to assisting the company at this exciting
stage.”
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of inflammation and
immuno-oncology. Humanigen’s immediate focus is to prevent or
minimize cytokine release syndrome that precedes severe lung
dysfunction in hospitalized and hypoxic patients with COVID-19
pneumonia. Humanigen is also exploring the effectiveness of
lenzilumab in other inflammatory conditions such as acute Graft
versus Host Disease (GvHD) in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT) and cytokine release
syndrome associated with CAR-T, bispecific, and other
T-cell-engaging therapies, eosinophilic asthma, and rheumatoid
arthritis. For more information, visit www.humanigen.com and follow
Humanigen on LinkedIn, Twitter, and Facebook.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment, and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct, and
you should be aware that actual events or results may differ
materially from those contained in the forward-looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding the potential commercialization
and distribution of lenzilumab if emergency use authorization were
granted, and other statements regarding Humanigen’s beliefs
relating to the technologies in Humanigen’s current pipeline.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the risks inherent in
the company’s lack of profitability and potential need for
additional capital to grow its business; its dependence on partners
to further the development of its product candidates; the
uncertainties inherent in the development, attainment of the
requisite regulatory authorizations and approvals and launch of any
new pharmaceutical product; the outcome of pending or future
litigation; and the various risks and uncertainties described in
the "Risk Factors" sections and elsewhere in Humanigen's periodic
and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. The
company undertakes no obligation to revise or update any
forward-looking statements made in this presentation to reflect
events or circumstances after the date hereof, to reflect new
information or the occurrence of unanticipated events, to update
the reasons why actual results could differ materially from those
anticipated in the forward-looking statements, in each case, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210607005168/en/
Humanigen Media Grace Catlett RXMD Gcatlett@rxmedyn.com
516-318-8563 Humanigen Investor Relations Ken Trbovich
Humanigen trbo@humanigen.com 650-410-3206
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024